Interferon induction and function at the mucosal surface

Immunological Reviews

Volumn 255, Issue 1, 2013, Pages 25-39

  Durbin, Russell K ^a   Kotenko, Sergei V ^b   Durbin, Joan E ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

IFN induction; Influenza A virus; Interferon; Respiratory syncytial virus; Rotavirus; Stat signaling

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; BETA INTERFERON; CRK LIKE PROTEIN; DNA METHYLTRANSFERASE 1; INTERFERON; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 9; INTERFERON STIMULATED GENE FACTOR 3; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 28A; INTERLEUKIN 28B; INTERLEUKIN 29; INTERLEUKIN 6; JANUS KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE TYK2; RECEPTOR FOR ACTIVATED C KINASE 1; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA;

ACETYLATION; ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; CELL METABOLISM; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CYTOKINE PRODUCTION; DNA SEQUENCE; GASTROINTESTINAL MUCOSA; GENE CONTROL; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; INFLUENZA VIRUS A; INNATE IMMUNITY; INTERFERON INDUCTION; INTRACELLULAR SIGNALING; MOLECULAR DOCKING; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT MUCOSA; REVIEW; ROTAVIRUS; SIGNAL TRANSDUCTION; SUMOYLATION; TRANSLATION INITIATION; VIRUS REPLICATION;

IFN INDUCTION; INFLUENZA A VIRUS; INTERFERON; RESPIRATORY SYNCYTIAL VIRUS; ROTAVIRUS; STAT SIGNALING;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; INTERFERONS; JANUS KINASES; LIGANDS; MUCOUS MEMBRANE; PHOSPHORYLATION; PROTEIN BIOSYNTHESIS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TOLL-LIKE RECEPTORS; VIRUS DISEASES; VIRUSES;

EID: 84881658991     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12101     Document Type: Review

References (168)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957;147:258-267.
2. Weissenbach J, et al. Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci USA 1980;77:7152-7156.
3. Taniguchi T, Fujii-Kuriyama Y, Muramatsu M. Molecular cloning of human interferon cDNA. Proc Natl Acad Sci USA 1980;77:4003-4006.
4. Weck PK, Apperson S, May L, Stebbing N. Comparison of the antiviral activities of various cloned human interferon-alpha subtypes in mammalian cell cultures. J Gen Virol 1981;57:233-237.
5. Streuli M, Hall A, Boll W, Stewart WE 2nd, Nagata S, Weissmann C. Target cell specificity of two species of human interferon-alpha produced in Escherichia coli and of hybrid molecules derived from them. Proc Natl Acad Sci USA 1981;78:2848-2852.
6. Wetzel R, et al. Properties of a human alpha-interferon purified from E. coli extracts. J Interferon Res 1981;1:381-390.
7. Kotenko SV. IFN-lambdas. Curr Opin Immunol 2011;23:583-590.
8. Sinaniotis CA. Viral pneumoniae in children: incidence and aetiology. Paediatr Resp Rev 2004;5:S197-S200.
9. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344:1917-1928.
10. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 2004;22:275-284.
11. Greenberg HB, Estes MK. Rotaviruses: from pathogenesis to vaccination. Gastroenterology 2009;136:1939-1951.
12. LaFleur DW, et al. Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem 2001;276:39765-39771.
13. Buontempo PJ, Jubin RG, Buontempo CA, Wagner NE, Reyes GR, Baroudy BM. Antiviral activity of transiently expressed IFN-kappa is cell-associated. J Interferon Cytokine Res 2006;26:40-52.
14. Fung KY, et al. Interferon-epsilon protects the female reproductive tract from viral and bacterial infection. Science 2013;339:1088-1092.
15. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem 2009;284:20869-20875.
16. Prokunina-Olsson L, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013;45:164-171.
17. Langer JA, Cutrone EC, Kotenko S. The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. Cytokine Growth Factor Rev 2004;15:33-48.
18. Yan H, Piazza F, Krishnan K, Pine R, Krolewski JJ. Definition of the interferon-alpha receptor-binding domain on the TYK2 kinase. J Biol Chem 1998;273:4046-4051.
19. Usacheva A, et al. Contribution of the Box 1 and Box 2 motifs of cytokine receptors to Jak1 association and activation. J Biol Chem 2002;277:48220-48226.
20. Kotenko SV, Izotova LS, Mirochnitchenko OV, Lee C, Pestka S. The intracellular domain of interferon-alpha receptor 2c (IFN-alphaR2c) chain is responsible for Stat activation. Proc Natl Acad Sci USA 1999;96:5007-5012.
21. Nadeau OW, et al. The proximal tyrosines of the cytoplasmic domain of the beta chain of the type I interferon receptor are essential for signal transducer and activator of transcription (Stat) 2 activation. Evidence that two Stat2 sites are required to reach a threshold of interferon alpha-induced Stat2 tyrosine phosphorylation that allows normal formation of interferon-stimulated gene factor 3. J Biol Chem 1999;274:4045-4052.
22. Wagner TC, et al. Interferon signaling is dependent on specific tyrosines located within the intracellular domain of IFNAR2c. Expression of IFNAR2c tyrosine mutants in U5A cells. J Biol Chem 2002;277:1493-1499.
23. Yan H, et al. Phosphorylated interferon-alpha receptor 1 subunit (IFNaR1) acts as a docking site for the latent form of the 113 kDa STAT2 protein. EMBO J 1996;15:1064-1074.
24. Leung S, Qureshi SA, Kerr IM, Darnell JE Jr, Stark GR. Role of STAT2 in the alpha interferon signaling pathway. Mol Cell Biol 1995;15:1312-1317.
25. Gibbs VC, Takahashi M, Aguet M, Chuntharapai A. A negative regulatory region in the intracellular domain of the human interferon-alpha receptor. J Biol Chem 1996;271:28710-28716.
26. Zhao W, et al. A conserved IFN-alpha receptor tyrosine motif directs the biological response to type I IFNs. J Immunol 2008;180:5483-5489.
27. Bhattacharya S, et al. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature 1996;383:344-347.
28. Paulson M, Press C, Smith E, Tanese N, Levy DE. IFN-Stimulated transcription through a TBP-free acetyltransferase complex escapes viral shutoff. Nat Cell Biol 2002;4:140-147.
29. Nusinzon I, Horvath CM. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc Natl Acad Sci USA 2003;100:14742-14747.
30. Chang HM, et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci USA 2004;101:9578-9583.
31. Huang M, Qian F, Hu Y, Ang C, Li Z, Wen Z. Chromatin-remodelling factor BRG1 selectively activates a subset of interferon-alpha-inducible genes. Nat Cell Biol 2002;4:774-781.
32. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 2005;5:375-386.
33. van Boxel-Dezaire AH, Rani MR, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 2006;25:361-372.
34. Uddin S, et al. Protein kinase C-delta (PKC-delta) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem 2002;277:14408-14416.
35. Pilz A, Ramsauer K, Heidari H, Leitges M, Kovarik P, Decker T. Phosphorylation of the Stat1 transactivating domain is required for the response to type I interferons. EMBO Rep 2003;4:368-373.
36. Ng SL, et al. IkB kinase epsilon regulates the balance between type I and type II interferon responses. Proc Natl Acad Sci USA 2011;108:21170-21175.
37. Perwitasari O, Cho H, Diamond MS, Gale M Jr. Inhibitor of kappaB kinase epsilon (IKK(epsilon)), STAT1, and IFIT2 proteins define novel innate immune effector pathway against West Nile virus infection. J Biol Chem 2011;286:44412-44423.
38. Tenoever BR, Ng SL, Chua MA, McWhirter SM, Garcia-Sastre A, Maniatis T. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 2007;315:1274-1278.
39. Wieczorek M, Ginter T, Brand P, Heinzel T, Kramer OH. Acetylation modulates the STAT signaling code. Cytokine Growth Factor Rev 2012;23:293-305.
40. Kramer OH, et al. Acetylation of Stat1 modulates NF-kappaB activity. Genes Dev 2006;20:473-485.
41. Kramer OH, Heinzel T. Phosphorylation-acetylation switch in the regulation of STAT1 signaling. Mol Cell Endocrinol 2010;315:40-48.
42. Antunes F, Marg A, Vinkemeier U. STAT1 signaling is not regulated by a phosphorylation-acetylation switch. Mol Cell Biol 2011;31:3029-3037.
43. Tang X, et al. Acetylation-dependent signal transduction for type I interferon receptor. Cell 2007;131:93-105.
44. Cheon H, Stark GR. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci USA 2009;106:9373-9378.
45. Cheon H, Yang J, Stark GR. The functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins. J Interferon Cytokine Res 2011;31:33-40.
46. Uddin S, et al. The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins. J Biol Chem 2000;275:27634-27640.
47. Grumbach IM, et al. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells. Br J Haematol 2001;112:327-336.
48. Kaur S, et al. Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling. J Immunol 2008;181:7316-7323.
49. Rusinova I, et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res 2013;41:D1040-D1046.
50. Schoggins JW, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011;472:481-485.
51. Sadler AJ, et al. Interferon -inducible antiviral effectors. Nat Rev Immunol 2008;8:559-568.
52. Jouvenet N, et al. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J Virol 2009;83:1837-1844.
53. Fitzgerald KA. The interferon inducible gene: viperin. J Interferon Cytokine Res 2011;31:131-135.
54. Jamaluddin M, et al. IFN-beta mediates coordinate expression of antigen-processing genes in RSV-infected pulmonary epithelial cells. Am J Physiol 2001;280:L248-L257.
55. Zhang D, Zhang DE. Interferon-stimulated gene 15 and the protein ISGylation system. J Interferon Cytokine Res 2011;31:119-130.
56. Piganis RA, et al. Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2. J Biol Chem 2011;286:33811-33818.
57. Malakhova OA, et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J 2006;25:2358-2367.
58. ten Hoeve J, et al. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 2002;22:5662-5668.
59. Song L, Bhattacharya S, Yunus AA, Lima CD, Schindler C. Stat1 and SUMO modification. Blood 2006;108:3237-3244.
60. Navarro S, Colamonici OR, Llombart-Bosch A. Immunohistochemical detection of the type I interferon receptor in human fetal, adult, and neoplastic tissues. Mod Pathol 1996;9:150-156.
61. Kotenko SV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4:69-77.
62. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008;4:e1000017.
63. Mordstein M, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol 2010;84:5670-5677.
64. Pulverer JE, et al. Temporal and spatial resolution of type I and III interferon responses in vivo. J Virol 2010;84:8626-8638.
65. Ank N, et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 2008;180:2474-2485.
66. Mordstein M, et al. Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog 2008;4:e1000151.
67. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 2004;279:32269-32274.
68. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 2005;31:109-118.
69. Sheppard P, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63-68.
70. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86:973-983.
71. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-397.
72. Arpaia N, Barton GM. Toll-like receptors: key players in antiviral immunity. Curr Opin Virol 2011;1:447-454.
73. Barbalat R, Ewald SE, Mouchess ML, Barton GM. Nucleic acid recognition by the innate immune system. Annu Rev Immunol 2011;29:185-214.
74. Barber GN, Cytoplasmic DNA. innate immune pathways. Immunol Rev 2011;243:99-108.
75. Rathinam VA, Fitzgerald KA. Cytosolic surveillance and antiviral immunity. Curr Opin Virol 2011;1:455-462.
76. Rathinam VA, Fitzgerald KA. Innate immune sensing of DNA viruses. Virology 2011;411:153-162.
77. Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008;89:1-47.
78. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-738.
79. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801.
80. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat Immunol 2003;4:161-167.
81. Yamamoto M, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003;301:640-643.
82. Hacker G, Suttner K, Harada H, Kirschnek S. TLR-dependent Bim phosphorylation in macrophages is mediated by ERK and is connected to proteasomal degradation of the protein. Int Immunol 2006;18:1749-1757.
83. Sato S, et al. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J Immunol 2003;171:4304-4310.
84. Jiang Z, Mak TW, Sen G, Li X. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proc Natl Acad Sci USA 2004;101:3533-3538.
85. Fitzgerald KA, et al. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003;4:491-496.
86. Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R, Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science 2003;300:1148-1151.
87. Uematsu S, et al. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J Exp Med 2005;201:915-923.
88. Marie I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J 1998;17:6660-6669.
89. Izaguirre A, et al. Comparative analysis of IRF and IFN-alpha expression in human plasmacytoid and monocyte-derived dendritic cells. J Leukoc Biol 2003;74:1125-1138.
90. Sato M, et al. Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 2000;13:539-548.
91. Honda K, et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005;434:772-777.
92. Onoguchi K, et al. Viral infections activate types I and III interferon genes through a common mechanism. J Biol Chem 2007;282:7576-7581.
93. Osterlund P, Pietila T, Veckman V, Kotenko S, Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. J Immunol 2007;179:3434-3442.
94. Yoneyama M, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004;5:730-737.
95. Pichlmair A, et al. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5′-phosphates. Science 2006;314:997-1001.
96. Hornung V, et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science 2006;314:994-997.
97. Garcia-Sastre A. Induction and evasion of type I interferon responses by influenza viruses. Virus Res 2011;162:12-18.
98. Bao X, Liu T, Spetch L, Kolli D, Garofalo RP, Casola A. Airway epithelial cell response to human metapneumovirus infection. Virology 2007;368:91-101.
99. Sen A, Pruijssers AJ, Dermody TS, Garcia-Sastre A, Greenberg HB. The early interferon response to rotavirus is regulated by PKR and depends on MAVS/IPS-1, RIG-I, MDA-5, and IRF3. J Virol 2011;85:3717-3732.
100. Broquet AH, Hirata Y, McAllister CS, Kagnoff MF. RIG-I/MDA5/MAVS are required to signal a protective IFN response in rotavirus-infected intestinal epithelium. J Immunol 2011;186:1618-1626.
101. Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity 2010;32:305-315.
102. Abreu M. TLR signalling in the intestinal epithelium: how bactrerial recognition shapes intestinal function. Nat Rev Immunol 2010;10:131-144.
103. Ioannidis I, Ye F, McNally B, Willette M, Flano E. Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells. J Virol 2013;87:3261-3270.
104. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-1531.
105. Lund JM, et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 2004;101:5598-5603.
106. Jewell NA, et al. Differential type I interferon induction by respiratory syncytial virus and influenza a virus in vivo. J Virol 2007;81:9790-9800.
107. Jewell NA, et al. Lambda interferon is the predominant interferon induced by influenza A virus infection in vivo. J Virol 2010;84:11515-11522.
108. Le Goffic R, et al. Cutting edge: influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J Immunol 2007;178:3368-3372.
109. Kato H, et al. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005;23:19-28.
110. Le Goffic R, et al. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog 2006;2:e53.
111. Rudd BD, et al. Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J Immunol 2006;176:1937-1942.
112. Bhoj V, et al. MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus. PNAS 2008;105:14046-14051.
113. Hornung V, et al. Replication-dependent potent IFN-alpha induction in human plasmacytoid dendritic cells by a single-stranded RNA virus. J Immunol 2004;173:5935-5943.
114. Kurt-Jones EA, et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000;1:398-401.
115. Rallabhandi P, et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol 2006;177:322-332.
116. Kumagai Y, et al. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity 2007;27:240-252.
117. Sen A, et al. Innate immune response to homologous rotavirus infection in the small intestinal villous epithelium at single-cell resolution. Proc Natl Acad Sci USA 2012;109:20667-20672.
118. Estes MK, Kapikian AZ. Rotaviruses. In: Knipe DM, Howley PM, eds. Fields Virology, 5th edn. Philadelphia, PA: Lippincott, Williams & Wilkins, 2007:1917-1974.
119. Deal EM, Jaimes MC, Crawford SE, Estes MK, Greenberg HB. Rotavirus structural proteins and dsRNA are required for the human primary plasmacytoid dendritic cell IFNalpha response. PLoS Pathog 2010;6:e1000931.
120. Maniatis T, et al. Structure and function of the interferon-beta enhanceosome. Cold Spring Harb Symp Quant Biol 1998;63:609-620.
121. Thomson SJ, et al. The role of transposable elements in the regulation of IFN-lambda1 gene expression. Proc Natl Acad Sci USA 2009;106:11564-11569.
122. Wang J, et al. Differentiated human alveolar type II cells secrete antiviral IL-29 (IFN-lambda1) in response to influenza A infection. J Immunol 2009;182:1296-1304.
123. Lasfar A, et al. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 2006;66:4468-4477.
124. Garcia-Sastre A, et al. The role of interferon in influenza virus tissue tropism. J Virol 1998;72:8550-8558.
125. Price G, Gaszewska-Mastarlarz A, Moskophidis D. The role of alpha/beta and gamma interferons in development of immunity to influenza A virus in mice. J Virol 2000;74:3996-4003.
126. Johnson TR, et al. Role for innate IFNs in determining respiratory syncytial virus immunopathology. J Immunol 2005;174:7234-7241.
127. Feng N, et al. Role of interferon in homologous and heterologous rotavirus infection in the intestines and extraintestinal organs of suckling mice. J Virol 2008;82:7578-7590.
128. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006;80:4501-4509.
129. Pott J, et al. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci USA 2011;108:7944-7949.
130. Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K, Fukuhara S. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol 2001;166:2961-2969.
131. Montoya M, et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 2002;99:3263-3271.
132. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001;14:461-470.
133. Padovan E, Spagnoli GC, Ferrantini M, Heberer M. IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol 2002;71:669-676.
134. Mattei F, Schiavoni G, Belardelli F, Tough DF. IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation. J Immunol 2001;167:1179-1187.
135. Le Bon A, et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003;4:1009-1015.
136. van Boxel-Dezaire AH, Zula JA, Xu Y, Ransohoff RM, Jacobberger JW, Stark GR. Major differences in the responses of primary human leukocyte subsets to IFN-beta. J Immunol 2010;185:5888-5899.
137. Gil MP, Salomon R, Louten J, Biron CA. Modulation of STAT1 protein levels: A mechanism shaping CD8 T-cell responses in vivo. Blood 2006;107:987-993.
138. Gil MP, et al. Regulating type 1 IFN effects in CD8 T cells during viral infections: changing STAT4 and STAT1 expression for function. Blood 2012;120:3718-3728.
139. Witte K, et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009;10:702-714.
140. Doyle SE, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006;44:896-906.
141. Zhang S, Kodys K, Li K, Szabo G. Human type 2 myeloid dendritic cells produce interferon-lambda and amplify interferon-alpha in response to hepatitis C virus infection. Gastroenterology 2013;144:414-425 e419.
142. Megjugorac NJ, Gallagher GE, Gallagher G. Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29). J Leukoc Biol 2009;86:1359-1363.
143. Wolk K, et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 2008;83:1181-1193.
144. Mennechet FJ, Uze G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006;107:4417-4423.
145. Yin Z, et al. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol 2012;189:2735-2745.
146. Dolganiuc A, et al. Type III interferons, IL-28 and IL-29, are increased in chronic HCV infection and induce myeloid dendritic cell-mediated FoxP3+ regulatory T cells. PLoS ONE 2012;7:e44915.
147. Liu BS, Janssen HL, Boonstra A. IL-29 and IFNalpha differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNgamma receptor expression. Blood 2011;117:2385-2395.
148. Dai J, Megjugorac NJ, Gallagher GE, Yu RY, Gallagher G. IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 2009;113:5829-5838.
149. He S, et al. Interferon-lambda mediates oral tolerance and inhibits antigen-specific, T-helper 2 cell-mediated inflammation. Gastroenterology 2011;141:249-258.
150. Koltsida O, et al. IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med 2011;3:348-361.
151. Morrow MP, et al. Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques. Clin Vaccine Immunol 2010;17:1493-1499.
152. Morrow MP, et al. IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther 2010;18:1714-1723.
153. Richter MF, Dumenil G, Uze G, Fellous M, Pellegrini S. Specific contribution of Tyk2 JH regions to the binding and the expression of the interferon alpha/beta receptor component IFNAR1. J Biol Chem 1998;273:24723-24729.
154. David M, Petricoin E 3rd, Benjamin C, Pine R, Weber MJ, Larner AC. Requirement for MAP kinase (ERK2) activity in interferon alpha- and interferon beta-stimulated gene expression through STAT proteins. Science 1995;269:1721-1723.
155. Usacheva A, et al. The WD motif-containing protein receptor for activated protein kinase C (RACK1) is required for recruitment and activation of signal transducer and activator of transcription 1 through the type I interferon receptor. J Biol Chem 2001;276:22948-22953.
156. Nguyen VP, et al. Stat2 binding to the interferon-alpha receptor 2 subunit is not required for interferon-alpha signaling. J Biol Chem 2002;277:9713-9721.
157. Uddin S, Chamdin A, Platanias LC. Interaction of the transcriptional activator Stat-2 with the type I interferon receptor. J Biol Chem 1995;270:24627-24630.
158. Bluyssen HA, et al. Combinatorial association and abundance of components of interferon-stimulated gene factor 3 dictate the selectivity of interferon responses. Proc Natl Acad Sci USA 1995;92:5645-5649.
159. Yang CH, et al. Direct association of STAT3 with the IFNAR-1 chain of the human type I interferon receptor. J Biol Chem 1996;271:8057-8061.
160. Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood 1999;93:1980-1991.
161. Gupta S, Jiang M, Pernis AB. IFN-alpha activates Stat6 and leads to the formation of Stat2:Stat6 complexes in B cells. J Immunol 1999;163:3834-3841.
162. Tang X, et al. Acetylation-dependent signal transduction for type I interferon receptor. Cell 2007;131:93-105.
163. Rani MR, et al. Catalytically active TYK2 is essential for interferon-beta-mediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase. J Biol Chem 1999;274:32507-32511.
164. Du Z, Shen Y, Yang W, Mecklenbrauker I, Neel BG, Ivashkiv LB. Inhibition of IFN-alpha signaling by a PKC- and protein tyrosine phosphatase SHP-2-dependent pathway. Proc Natl Acad Sci USA 2005;102:10267-10272.
165. Abramovich C, Yakobson B, Chebath J, Revel M. A protein-arginine methyltransferase binds to the intracytoplasmic domain of the IFNAR1 chain in the type I interferon receptor. EMBO J 1997;16:260-266.
166. Zheng H, Qian J, Varghese B, Baker DP, Fuchs S. Ligand-stimulated downregulation of the alpha interferon receptor: role of protein kinase D2. Mol Cell Biol 2011;31:710-720.
167. David M, Zhou G, Pine R, Dixon JE, Larner AC. The SH2 domain-containing tyrosine phosphatase PTP1D is required for interferon alpha/beta-induced gene expression. J Biol Chem 1996;271:15862-15865.
168. Kumar KG, Tang W, Ravindranath AK, Clark WA, Croze E, Fuchs SY. SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J 2003;22:5480-5490.